



# NCCTG

NORTH CENTRAL CANCER TREATMENT GROUP

---

## Operations Office

---

TO: Principal Investigators and Primary Clinical Research Associates

FROM: Janis Wobschall  
Protocol Development Coordinator

DATE: March 19, 2010

SUBJECT: N0272, Phase I/II Trial of Imatinib Mesylate; (Gleevec; STI571) in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma

Attached is an updated Eligibility Checklist for this protocol. Edits are as follows:

| CRF Title             | Brief Description of Edit  |
|-----------------------|--|
| Eligibility Checklist | <ul style="list-style-type: none"><li>Removed IRB verbiage for Addendums 11 and 12 on the bottom of page 1</li></ul> |

Please note this updated checklist is not in conjunction with an addendum.

If you have any questions, please feel free to contact me at 507/538-8226.

Thank you.